Interestingly, in a diet-induced obesity mouse model, Sun et al. reported that glycoursodeoxycholate may act as an intestinal farnesoid X receptor (FXR) antagonist, and substantially attenuated body weight gain, and restored glucose intolerance and insulin resistance without disorders in bile acid metabolism and liver injury [96]. Here, NR1H4 is linked to obesity disorder.